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ABSTRACT
Identification of novel biomarkers for tumor-initiating cells (TICs) is of critical 
importance for developing diagnostic and therapeutic strategies against cancers. 
Here we identified the role of KIAA1114, a full-length translational product of the 
trophinin gene, as a distinctive marker for TICs in human liver cancer by developing 
a DNA vaccine-induced monoclonal antibody targeting the putative extracellular 
domain of KIAA1114. Compared with other established markers of liver TICs, 
KIAA1114 was unique in that its expression was detected in both alpha fetoprotein 
(AFP)-positive and AFP-negative hepatocellular carcinoma (HCC) cell lines with 
the expression levels of KIAA1114 being positively correlated to their tumorigenic 
potentials. Notably, KIAA1114 expression was strongly detected in primary hepatic 
tumor, but neither in the adjacent non-tumorous tissue from the same patient nor 
normal liver tissue. KIAA1114high cells isolated from HCC cell lines displayed TIC-like 
features with superior functional and phenotypic traits compared to their KIAA1114low 
counterparts, including tumorigenic abilities in xenotransplantation model, in vitro 
colony- and spheroid-forming capabilities, expression of stemness-associated genes, 
and migratory capacity. Our findings not only address the value of a novel antigen, 
KIAA1114, as a potential diagnostic factor of human liver cancer, but also as an 
independent biomarker for identifying TIC populations that could be broadly applied 
to the heterogeneous HCC subtypes.
INTRODUCTION
Durable complete remission has been rarely 
achieved with conventional anticancer strategies owing 
to sustained survival or continuous reappearance of 
therapy-resistant tumor cells that cause locoregional 
relapse and distant metastasis. Such observation led to the 
emergence of “cancer stem cell” hypothesis that tumors, 
like normal somatic tissues, contain distinct stem cell-
like populations having strong regeneration capacity and 
drug resistance. The exact definition of “cancer stem cells 
(CSCs)” was recently provided by Valent et al. that CSCs 
are a subset of neoplastic stem cells that drives indefinite 
proliferation of malignant clones and production of an 
apparent cancer [1]. They also suggested that the term 
“tumor-initiating cells (TICs)”, which has been widely 
used to describe experimentally identified CSCs, may be 
applied to characterize cells that are capable of initiating 
the formation of a detectable, continuously growing tumor 
in xenograft models [1]. CSCs are thought to stand at the 
pinnacle of tumor hierarchy and be capable of producing 
differentiated progenies to recapitulate the clonal 
heterogeneity of parental tumors [2]. Thus, the resistance 
of tumors to existing therapies as well as their recurrence 
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and metastatic spread are possibly due to the existence 
of CSCs bearing indefinite self-renewal capacities. CSCs 
tend to express elevated levels of ATP-binding cassette 
(ABC) transporters, aldehyde dehydrogenase 1, pro-
survival and DNA repair proteins, all of which contribute 
to their intrinsic drug resistance [3]. In addition, a number 
of studies on the metastasis of solid tumors have shown 
that epithelial-mesenchymal transition (EMT) triggers 
cells located at the invasive edge of the primary tumor 
to obtain stemness properties along with motility and 
invasiveness, and these migrating CSCs are endowed with 
the unique abilities to colonize and initiate tumor growth 
at the secondary site [4, 5]. Considerable efforts have been 
made over the last few decades to identify surface markers 
that are exclusively expressed on CSCs, as developing 
therapeutics targeting CSCs will undoubtedly open new 
ways for the treatment of human cancers. Despite the 
comprehensive list of CSC markers, however, clinical 
transition of most available markers has been rarely 
achieved since the application of a sole marker for broad 
range of tumor subtypes has been frequently hampered 
by intertumoral and intratumoral heterogeneity of a given 
cancer.
In human hepatocellular carcinoma (HCC), a 
number of TIC markers have been identified including 
CD133, EpCAM, and CD90, whose functions were 
well-characterized using both cell lines and primary 
tumor specimens [6]. Importantly, however, none of 
these markers were universally expressed within diverse 
subtypes of liver cancer. In HCC cell lines, which can 
be classified by alpha fetoprotein (AFP) status [7], 
expressions of CD133 and EpCAM were only detected 
in AFP+ cells, whereas CD90 expression was exclusively 
found in AFP− counterparts [8]. Furthermore, in primary 
HCC, not only did the level of EpCAM and CD90 
expression vary greatly among different individuals, but 
the cell populations expressing EpCAM and CD90 were 
distinctively localized without overlap even in a given 
tumor derived from a single patient [9]. These findings 
provide clear evidence for the existence of heterogeneity 
in primary liver cancer and the differential expression 
pattern of TIC markers depending on HCC subtypes. 
Therefore, further identification of biomarkers that could 
be broadly used to identify TICs from multiple tumor 
subtypes may bring significant clinical benefits in terms 
of diagnosis and therapy.
MAGE (Melanoma-associated antigen) superfamily 
proteins have been considered as attractive therapeutic 
targets owing to their specific expression in cancer. 
MAGE-D genes are recently discovered MAGE subfamily 
with distinguished features in terms of their genomic 
structures and expression patterns. Among the members 
of MAGE-D family, trophinin (also known as MAGE-D3) 
is particularly unique in that it can encode multiple 
translational products having pleiotropic functions in 
various biological processes. Previous reports have 
suggested that the presence of numerous translational 
initiation sites in trophinin mRNA and utilization of 
different alternative splicing could generate three major 
types of proteins – KIAA1114, TROPHININ, and 
MAGPHININs [10, 11]. Although a number of studies 
have been performed on dissecting the physiological role 
and function of TROPHININ in embryo implantation 
and cancer progression [12], only few studies have 
been conducted on a full-length protein encoded by 
the trophinin gene known as KIAA1114, whose cDNA 
coding sequence was initially identified from human 
brain [13]. Despite the reported expression of KIAA1114 
at the transcriptional level, physiological evidence for the 
existence of KIAA1114 at the protein level has never been 
reported to date, making it a “hypothetical” protein for 
more than a decade.
In this study, we provide the first direct evidence for 
the presence of KIAA1114 at the protein level in cancer 
cells by utilizing a monoclonal antibody (mAb) raised 
against the extracellular domain of KIAA1114 antigen and 
propose its potential role as a prognostic factor, and more 
significantly, as a distinctive and versatile TIC surface 
marker for multiple subtypes of human liver cancer.
RESULTS
KIAA1114, the full-length translation product of 
the trophinin gene, is a transmembrane protein 
localized on the cell surface
The nomenclature for a full-length protein encoded 
by the trophinin gene has not been well-defined [11, 
14], as experimental evidence for the expression of 
KIAA1114 in vitro or in vivo has never been provided 
by earlier studies. In the present study, we used the term 
“KIAA1114” to describe the full-length product translated 
from trophinin mRNA (Figure 1A). Hydropathy analysis 
using the topology prediction program TMpred [15] 
revealed that KIAA1114 is a transmembrane protein with 
the N-terminus outside the cell (Supplementary Figure 1). 
Moreover, as previously suggested [16], KIAA1114 is 
predicted to contain an intracellular MAGE-homology 
domain and a trophinin domain that traverses the plasma 
membrane. Although hydropathy analyses performed in 
the present and previous studies proposed that a trophinin 
domain spans the lipid bilayer multiple times [17], a 
recent review raised a possibility that TROPHININ is a 
single-pass, type II transmembrane protein that utilizes 
the majority of its extracellular decapeptide repeats for 
homophilic adhesion [18]. Accordingly, we proposed 
that KIAA1114 is a double-pass, type III transmembrane 
protein with N- and C-termini facing the outside of the 
cell (Figure 1B). Although thorough structural analysis 
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Figure 1: Identification and localization of KIAA1114 with a novel anti-KIAA1114 mAb, Kiatomab. (A) Schematic 
structures of human MAGE-D3 gene, transcript, and protein products – KIAA1114 and TROPHININ (MAGPHININ proteins are not 
shown). Regions recognized by Kiatomab and anti-TROPHININ mAb (3–11) are indicated. (B) Schematic diagram showing putative 
transmembrane topology of KIAA1114 protein. Predicted locations of TROPHININ domain, MAGE homology domain (MHD), and partial 
N-terminal domain encoded by DNA vaccine used for Kiatomab generation are indicated. 
(Continued)
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Figure 1: (C) Western blot and flow cytometric analysis for recognition of human and mouse KIAA1114 by Kiatomab and 3–11 mAb 
using 293T cells and mouse brain tissue. β-actin was used as a loading control for Western blot. In flow cytometry, KIAA1114 expression 
is indicated as open histogram and isotype controls are represented as shaded histogram. (D) Analysis of KIAA1114 expression in various 
murine tissues by flow cytometry and Western blot. Isotype control and Kiatomab stainings are indicated as describe above for flow 
cytometry. Tubulin was used as an internal control for Western blot assay.
is required to determine exact location of transmembrane 
regions, TMPred suggested that the first membrane-
spanning segment lies within a MAGE-homology domain 
and the second one locates near the N-terminus of a 
trophinin domain (Supplementary Figure 1).
To develop a novel mAb targeting KIAA11114, mice 
were immunized with the gene encoding partial N-terminal 
extracellular domain of human MAGE-D3 (Figure 1B). 
DNA immunization was selected over conventional 
peptide/protein immunization, as it allows spontaneous 
formation of native folded proteins in vivo and subsequent 
generation of high-avidity antibodies recognizing antigens 
with proper conformation [19, 20]. To investigate whether 
the resulting mAb, named Kiatomab, could recognize 
human KIAA1114 protein, Western blot analysis was 
performed using human kidney 293T cell lysates, as the 
expression of magphinin/trophinin transcript in renal 
tissues has been previously suggested [21]. As a result, we 
found that Kiatomab reacted with a full-length, 138 kDa 
form of human KIAA1114. Nextly, to examine whether 
Kiatomab has cross-reactivity to mouse KIAA1114, 
further analysis was carried out on extracted proteins 
from mouse brain, which is known to express high 
level of trophinin transcripts [16]. Immunoblot analysis 
with Kiatomab revealed a single band corresponding to 
196 kDa mouse KIAA1114. The expression of human and 
mouse KIAA1114 in the same lysates were also identified 
by the commercial anti-TROPHININ mAb (clone 3–11) 
which was used as a positive control (Figure 1C, left 
panel). Moreover, the reactivity of Kiatomab to 293T 
and primary mouse brain cells was further confirmed 
by surface staining analysis, implicating the cell surface 
localization of KIAA1114. In contrast, 3–11 mAb failed 
to show noticeable reactivity in equivalent experimental 
conditions (Figure 1C, right panel). These findings differ 
from a prior study that detected cell surface expression of 
TROPHININ on stable transfectants of a human testicular 
seminoma cell line overexpressing TROPHININ using 
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3–11 mAb by flow cytometry [22]. The exact causes of 
these differences remain unclear, but the disparities in the 
nature of cell lines used (normal untransfected cells versus 
stably transfected cells) and subsequent discrepancies in 
the copy number of the genes encoding KIAA1114 or 
TROPHININ may partially be responsible for yielding 
distinct results.
To assess whether cell surface expression of 
KIAA1114 correlates with reported expression pattern of 
trophinin mRNA, KIAA1114 expression in primary cells 
derived from various murine tissues were analyzed by 
flow cytometry. Earlier gene expression profiling studies 
have suggested that trophinin or MAGE-D3 transcript 
could be detected in mouse brain, testis, and kidney (also 
in thymus, parathyroid gland, ovary, prostate, epididymus, 
and embryo), but not in the rest of the organs [16, 21]. 
In agreement with these reports, flow cytometric analysis 
with Kiatomab showed that KIAA1114 is expressed on the 
surface of cells of testis and kidney, but not by the cells 
of spleen and lung (Figure 1D), suggesting that surface 
binding of Kiatomab is specific to cells that express 
trophinin mRNA. KIAA1114 expression in these organs 
was also validated by Western blot analysis, showing the 
presence of KIAA1114-specific bands in testis and kidney, 
but not in spleen and lung.
Overall, these results not only provide the first 
empirical evidence that KIAA1114 is indeed expressed 
at the protein level, but also propose that it is localized 
mainly on the cell surface.
KIAA1114 is overexpressed in human liver 
cancer cell lines with aggressive characteristics 
and HCC patient’s primary tumor
Previous studies have suggested that the expression 
of TROPHININ was frequently observed in patients 
bearing malignant or metastatic tumors, including 
testicular germ tumor and adenocarcinomas of colon 
and lung [12]. To investigate whether KIAA1114 shows 
analogous pattern of expression in cancer, epithelial 
cell lines of various tissue origin were subjected to 
flow cytometric analysis. Kiatomab showed reactivity 
towards the majority of tumor cell lines, although the 
degree of KIAA1114 expression varied among different 
cell lines, even within those from the same tumor type 
(Supplementary Table 1).
Among the various types of tumors screened, we 
focused on exploring the role of KIAA1114 in human 
liver cancer, including HCC and cholangiocarcinoma 
(CC), based on our observation of the potential 
correlation between KIAA1114 expression levels and 
tumor progression. Firstly, in CC, KIAA1114 expression 
was significantly higher in sarcomatoid SCK cells 
than adenocarcinomatous cell lines, JCK, Cho-CK, 
and Choi-CK (Figure 2A). A prior study showed that 
SCK cells not only possessed strong resistance to 
chemotherapeutic agents, but also expressed elevated 
levels of genes involved in cancer progression and 
metastasis as well as EMT-associated markers [23, 24]. 
As sarcomatoid CCs are known to be more aggressive 
and have worse prognosis than adenocarcinomatous 
CCs [24], increased expression of KIAA1114 may 
contribute to the acquisition of an aggressive phenotype 
in CC. It was also worth noting that, among three 
adenocarcinomatous cell lines, Choi-CK cell line 
established from a stage IVB patient exhibited much 
higher KIAA1114 expression than did Cho-CK and 
JCK cells, both of which were derived from stage IVA 
patients [24].
The possible involvement of KIAA1114 in tumor 
progression was more thoroughly investigated in HCC. 
Among three AFP-producing HCC cell lines, HepG2 
cells showed the lowest level of KIAA1114 expression, 
whereas HuH7 cells displayed the highest expression level 
(Figure 2B). Based on previous studies that characterized 
in vivo tumorigenicity of different HCC cell lines 
(tumorigenicity in the order of HuH7 > Hep3B > HepG2) 
[25], we found that KIAA1114 expression correlates with 
tumorigenic potential. Similar results were observed in 
AFP− cell lines where highly tumorigenic SK-Hep-1 
cells displayed greater KIAA1114 expression than non-
tumorigenic SNU475 cells.
To assess the clinical relevance of KIAA1114 to 
human liver cancer, tissues lysates obtained from primary 
HCC, matched non-tumor, and normal liver were analyzed 
by Western blot for KIAA1114 expression. Kiatomab 
failed to detect the band that corresponds to KIAA1114 
in normal liver tissue from a healthy donor. This result is 
consistent with a previous study that showed the absence 
of trophinin (or MAGE-D3)-specific signal in the adult 
liver of mice by semiquantitative RNA dot blot analysis 
[16]. More importantly, KIAA1114 expression was solely 
detected in the primary liver tumor, but not in the adjacent 
non-malignant hepatic tissue derived from the same 
patient (Figure 2C).
KIAA1114high cells isolated from HCC cell lines 
possess TIC-like properties
Positive correlation between tumorigenicity of HCC 
cell lines and expression level of TIC markers has been 
observed in earlier studies. For example, the expression of 
CD133, the first TIC marker identified in liver cancer, was 
markedly higher in HCC cell lines having tumor-initiating 
capabilities in vivo compared to those lacking such 
capacities [26]. Similar results were obtained with another 
TIC marker CD90, whose expression level was closely 
associated with tumorigenic as well as metastatic potential 
of liver cancer cell lines [25]. Based on these results, 
we hypothesized that KIAA1114 may also be used as a 
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marker to isolate TIC population. To validate this, we first 
determined whether the expression pattern of KIAA1114 
overlapped with those of known liver TIC markers in HCC 
cell lines (Figure 3). Differential expression of various TIC 
markers between AFP+ and AFP− cells was also evaluated, 
as previous studies have shown that distinct prognostic 
subtypes of HCCs displayed distinguishable levels 
of expression for stem/maturation markers, including 
CD133 and CD90 (Supplementary Table 2) [8]. Firstly, 
the expression of KIAA1114 clearly overlapped with that 
of CD133 and EpCAM, both of which were expressed in 
AFP+ HCC cell lines. The level of CD133 and EpCAM 
expression was associated with tumorigenic potentials of 
AFP+ cell lines in general, as more tumorigenic Hep3B 
and HuH7 cells displayed significantly higher expression 
of those markers while less tumorigenic HepG2 cells 
showed no apparent expression. Nonetheless, CD133 
and EpCAM expressions did not distinguish HuH7 from 
Hep3B cells whose tumorigenic capacity was known to 
be inferior to the former. It was also important to note that 
both CD133 and EpCAM were not or minimally expressed 
by AFP− HCC cell lines. Conversely, CD90 expression 
was confined to AFP− cells, in which a fraction of CD90+ 
cells was co-localized with KIAA1114-expressing cells. 
Nevertheless, non-tumorigenic SNU475 cells expressed 
higher level of CD90 than highly tumorigenic SK-Hep-1 
cells. CD24 is a recently discovered liver TIC marker 
whose expression was found to be upregulated in residual 
chemoresistant HCC xenograft tumors [27]. Although 
this previous study reported that CD24 was expressed in 
AFP+ cell lines, including Hep3B and HuH7, as well as 
in a AFP− cell line, HLE, our results revealed that only 
AFP+ HuH7 cells expressed significantly high level of 
CD24 and displayed discernible co-localization of CD24+ 
and KIAA1114-expressing cells. Accordingly, a definite 
correlation between the extent of CD24 expression and 
Figure 2: KIAA1114 expression in human liver cancer cell lines and primary tumors. (A and B) Flow cytometric analysis of 
surface KIAA1114 expression in human CC cell lines (A) and AFP+ and AFP− HCC cell lines (B). (C) Immunoblot analysis of tissue lysates 
from normal liver (N), patient tumor (PT), and its adjacent normal tissue from the same donor (PN). β-actin served as an internal control.
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tumorigenic potentials of cell lines was only observed in 
AFP+ subtype. Lastly, flow cytometric analysis of CD13, 
a semiquiescent TIC marker regulating ROS-induced 
DNA damage [28], showed that its expression could 
be detected and overlapped with that of KIAA1114 in 
all cell lines tested, regardless of their AFP expression 
status. Yet, CD13 expression showed no correlation 
with tumorigenicity of HCC cell lines in any of the HCC 
subtypes. These findings suggest that KIAA1114 is a 
unique biomarker whose expression not only overlaps 
with diverse liver TIC markers, but also correlates with 
tumorigenic capacities of HCC cell lines in both AFP+ and 
AFP− subtypes.
Nextly, to investigate whether KIAA1114 could play 
a role as an independent marker to identify liver TICs, we 
isolated cell populations expressing high and low levels 
of KIAA1114 from AFP+ HuH7 cells and AFP− SK-Hep-1 
cells and comparatively assessed their functional 
capacities of TICs. As with previous studies of CD133 
and EpCAM expression analysis in human liver cancer 
[8, 26], HCC cell lines examined in this study exhibited 
a Gaussian distribution of KIAA1114 expression levels, 
rather than displaying a discrete, isolated population of 
KIAA1114+ cells. Therefore, sorted fractions obtained by 
FACS-selecting the top 10% most brightly stained cells 
were designated “KIAA1114high” cells, whereas those 
Figure 3: Overlapping expression between established liver TIC markers and KIAA1114. Flow cytometric analysis of HCC 
cell lines stained with antibodies against CD133, EpCAM, CD90, CD24, and CD13 in conjunction with Kiatomab. The quadrant marker of 
each plot was set on the basis of respective isotype control staining.
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derived from the bottom 10% most dimly stained cells 
were designated “KIAA1114low” cells. Assuming 95% 
purities of KIAA1114low cells after separation, the purities 
of KIAA1114high cells in HuH7 and SK-Hep-1 cells were 
84.3% and 57.6%, respectively (Figure 4A). Nextly, to 
evaluate clonogenic potential of isolated subpopulations, 
colony formation assay was performed. The result showed 
that the number of colonies generated from KIAA1114high 
populations was greater than that from KIAA1114low 
counterparts, regardless of AFP expression status of 
parental cells (Figure 4B). Analogously, sphere-formation 
assay, which was used as readout for self-renewal activity, 
revealed that KIAA1114high cells isolated from either 
HuH7 or SK-Hep-1 cell line formed significantly more 
spheroids than did KIAA1114low cells (Figure 4C). These 
findings suggest that KIAA1114high subsets possess higher 
proliferative potential and self-renewal capacity than 
KIAA1114low counterparts. We also noticed differences in 
qualitative aspects of spheres formed by AFP+ HuH7 and 
AFP− SK-Hep-1 cells. The size of each spheroid generated 
by KIAA1114high fraction was much larger than that of 
KIAA1114low fraction-derived one in HuH7 cells, while 
the spheres formed by KIAA1114high and KIAA1114low 
cells sorted from SK-Hep-1 cells were similar in size. 
Moreover, the overall sphere-forming efficiencies of 
sorted cells were relatively lower in SK-Hep-1 cells 
compared to HuH7 cells.
The assessment of differentiating capacity of 
isolated tumor cells is another criterion for evaluating 
TICs, as these cells are known to undergo asymmetric 
divisions to generate heterogeneous populations containing 
phenotypically diverse cell types [2]. Hence, we analyzed 
cell surface KIAA1114 expression on short-term passages 
of KIAA1114high and KIAA1114low subpopulations sorted 
from HuH7 and SK-Hep-1 cell lines by flow cytometry to 
analyze whether KIAA1114high HCC cells could produce 
KIAA1114low cells and vice versa. In both AFP+ and AFP− 
HCC subtypes, KIAA1114high cells generated increasing 
numbers of KIAA1114low cells until KIAA1114 expression 
reached steady-state levels (day 15), as shown by time-
dependent decreases in the fluorescence intensities, 
suggesting the differentiation of KIAA1114high cells into 
KIAA1114low counterparts (Supplementary Figure 2). 
Unexpectedly, we also observed gradual upregulation of 
KIAA1114 expression in KIAA1114low fractions, yielding 
contradictory results from previous reports of EpCAM 
and CD24 where EpCAM− and CD24− HCC fractions 
maintained their low marker expression status for 2 weeks 
in culture, respectively [8, 27]. However, our results are 
in line with a prior study of CD133 that showed increased 
CD133 surface expression upon culture in CD133− 
subsets isolated from HCC cell lines as well as xenograft 
tumors. These data were interpreted as the consequence of 
asymmetric division undergone by a small subset (~5%) of 
CD133+ cells contaminated in the CD133− population [26]. 
Therefore, considering the moderate purity of sorted HCC 
cells used in the present study (Figure 4A), it could be 
presumed that KIAA1114low subsets contain contaminating 
KIAA1114high cells abundant enough to generate both 
KIAA1114high and KIAA1114low populations.
Previous studies have shown that the majority of 
TICs, including those identified in HCC, exhibited elevated 
expression levels of “stemness” genes, which are defined 
as genes required for stem cell maintenance by conferring 
pluripotency, compared to their differentiated counterparts 
[29, 30]. In addition, TICs often display upregulated 
expression of ABC superfamily members that render 
them resistant to various types of therapies. Therefore, we 
assessed the expression levels of 8 stemness-associated 
genes (β-catenin, BMI-1, c-Myc, GDF3, KLF4, Nanog, 
POU5F1, and ZFP42) and 2 ABC transporter genes 
(ABCB1 and ABCG2) in KIAA1114high and KIAA1114low 
cells (Figure 4D). In HuH7 cells, 5 stemness-related genes 
(β-catenin, BMI1, c-Myc, KLF4, and ZFP42) and all of 
ABC transporter genes were upregulated in KIAA1114high 
fraction in a statistically significant manner. Among them, 
the expression levels of ABCG2, c-Myc, and ZFP42 were 
3- to 5-fold higher in KIAA1114high cells compared to 
KIAA1114low cells. Contrarily, the overexpression of 
stemness-associated genes was not clearly observed in 
AFP− SK-Hep-1 cell line with only 4 genes (ABCG2, 
BMI, c-Myc, and KLF4) showing marginal upregulation in 
KIAA1114high cells compared to KIAA1114low cells. Since 
AFP− HCC cell lines are reported to express genes related 
to EMT and mesenchymal lineages rather than hepatic 
stem cell-specific markers [9], sorted KIAA1114high and 
KIAA1114low SK-Hep-1 cells were then subjected to 
transwell migration assay, a common method for analyzing 
post-EMT activity [31]. Intriguingly, KIAA1114high 
fractions showed more than 3-fold higher migration rate 
compared to KIAA1114low counterpart. On the other 
hand, KIAA1114high and KIAA1114low cells isolated from 
HuH7 cells displayed comparable migration capacities 
(Figure 4E). These results suggest that KIAA1114high 
cells derived from SK-Hep-1 cells may retain discrete 
characteristics and gene expression profiles compared with 
those from HuH7 cells.
As mentioned earlier, the definition of TICs involves 
empirical evaluation of functional qualities of a given cell 
population, especially in its capacity to initiate and sustain 
tumor growth in immunodeficient mice. Accordingly, we 
assessed in vivo tumorigenic capacities of KIAA1114high 
and KIAA1114low cells by subcutaneously injecting them 
into beige/nude/xid mice. For HuH7 cell line, as few 
as 1,000 KIAA1114high cells were sufficient to establish 
tumors in 100% of mice, while the same number of 
KIAA1114low cells was unable to develop tumors in any of 
the mice injected. As many as 100,000 KIAA1114low cells 
were required to accomplish consistent tumor generation, 
indicating about 100-fold lower tumor-forming efficiency 
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Figure 4: TIC-like properties of KIAA1114high HCC cells. (A) Flow cytometric analysis of sorted KIAA1114high and KIAA1114low 
cells from HuH7 and SK-Hep-1 cell lines. (B) Colony formation assay of KIAA1114high and KIAA1114low fractions isolated from HuH7 and 
SK-Hep-1 cells. 2,000 sorted cells were seeded into 6-well plates in triplicate and cultured for 2 weeks. The resulting colonies were stained 
with crystal violet and counted under the microscope. Representative images are shown. *p <0.05; **p<0.01. (C) Sphere forming assay 
of purified cells. 2,000 KIAA1114high and KIAA1114low cells were plated in 6-well ultra-low attachment dishes and cultured for 2 weeks. 
Spheres were counted and photographed using the microscope. Scale bars: 500 μm. **p <0.01. (D) Quantitative real-time PCR analysis of 
stemness-related genes in KIAA1114high and KIAA1114low cells derived from HuH7 and SK-Hep-1.*p <0.05; **p<0.01. 
(Continued)
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compared to KIAA1114high counterpart. In the case of SK-
Hep-1 cell line, isolated KIAA1114high fraction not only 
developed tumors in 2 out of 4 mice with 10,000 cells, but 
also achieved 100% tumor incidence with 100,000 cells. 
On the contrary, KIAA1114low fraction failed to initiate 
tumors in any mice, even with the highest cell number 
examined (100,000 cells/site) (Table 1). Notably, 10,000 
HuH7-sorted KIAA1114high cells formed much larger 
tumors than did 100,000 SK-Hep-1-isolated KIAA1114high 
cells in the same amount of time (Figure 4F). This result 
is consistent with a previous study that EpCAM+ cells 
derived from AFP+ HCCs generated much larger and 
faster-growing tumors than did CD90+ cells purified from 
AFP− HCCs [9].
DISCUSSION
Cancer stem cells (CSCs), a tumorigenic 
subpopulation of cancer cells that drives unlimited 
propagation of malignant clones, are regarded as 
the major source of tumor recurrence and metastasis 
[32]. Accordingly, the identification and functional 
characterization of CSC-specific markers and phenotypic 
analysis of these marker-expressing cells are crucial for 
developing CSC-directed therapies. In the present study, 
we proposed the role of a novel tumor-associated antigen, 
KIAA1114, as a bona fide marker for liver CSCs, based 
on the functional and phenotypic features displayed 
by isolated KIAA1114high HCCs in several CSC assays. 
Firstly, anchorage-dependent colony formation assay 
revealed that KIAA1114high cells derived from both 
AFP+ and AFP− cell lines retained superior proliferative 
capacities than KIAA1114low cells. These results are in 
line with previous reports that showed enhanced colony-
forming abilities of CD133+ and EpCAM+ HCC cells 
compared to their respective CD133− and EpCAM− 
counterparts, but contrast with the studies that displayed 
slower growth rate of CD13+ and CD24+ sorted cells than 
corresponding marker-negative fractions [8, 26–28]. These 
findings suggest that KIAA1114high cells do not possess 
quiescent properties, which are occasionally ascribed 
to CSCs [2], as do CD13+ and CD24+ HCCs. Secondly, 
non-adherent sphere assay revealed that KIAA1114high 
subsets exhibited stronger self-renewal capacities than 
KIAA1114low subsets in both AFP+ and AFP− HCCs. 
Analogous results were obtained in a prior study, where 
CD133+ and EpCAM+ cells isolated from HuH7 cell 
line exhibited higher spheroid-forming efficiencies than 
CD133− and EpCAM− cells, respectively [33]. Thirdly, 
and most importantly, in vivo limiting dilution assay 
provided direct evidence that KIAA1114high fractions 
sorted from HCC cell lines had superior tumor-initiating 
capacities compared to KIAA1114low cells. Since the 
operational definition of CSC was developed based on the 
capacity of cells to initiate and maintain tumor growth in 
immunodeficient mice [1], it might be feasible to designate 
KIAA1114high HCCs as CSCs, or more accurately, TICs. 
Collectively, our findings suggest that KIAA1114high 
HCCs recapitulate some of the basic but essential features 
Figure 4: (E) Transwell migration assay of KIAA1114high and KIAA1114low subsets. 5 × 104 HuH7-sorted or 1 × 104 SK-Hep-1-sorted cells 
were seeded onto the upper chamber and incubated for 16 hours. Migrated cells were stained with Diff-Quik and counted. Representative 
microscopic fields are shown. Scale bars: 500 μm. **p <0.01. (F) Representative images of beige/nude/xid mice subcutaneously injected 
with 1 × 104 HuH7-sorted or 1 × 105 SK-Hep-1-sorted KIAA1114high cells (black arrow) and KIAA1114low cells (white arrow). The 
photographs were taken 3 months after injections. All graphically represented data are shown as average ± SEM.
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of existing liver TICs, including enhanced capacities for 
proliferation, self-renewal, and in vivo tumor generation, 
as those exhibited by CD133+ and EpCAM+ cells.
The reliability of existing liver TIC markers has 
been frequently challenged based on the heterogeneous 
and polyclonal nature of HCC that distinct phenotypic 
markers are expressed by different histological subtypes 
[34]. Previous studies have shown that HCC can be 
classified into four subtypes based on EpCAM and AFP 
expression status and each subtype has different molecular 
signatures and discrete signaling pathways that regulate 
its biological activities [35]. These results led us to focus 
on the investigation of differential expression patterns of 
KIAA1114 and known liver TIC markers between AFP+ 
and AFP− subtypes. Consistent with previous studies, 
our results showed that AFP+ cell lines expressed CD133 
and EpCAM, while AFP− cells only expressed CD90 [8]. 
On the other hand, KIAA1114 expression was detected 
in all cell lines tested and isolated KIAA1114high cells 
exhibited much stronger tumorigenic potential than did 
KIAA1114low cells in both HCC subtypes. Interestingly, 
however, stemness-associated gene expression profiles and 
migratory properties of KIAA1114high subsets were shown 
to be different in AFP+ HuH7 cells and AFP− SK-Hep-1 
cells. HuH7-isolated KIAA1114high cells exhibited 
tendency to express significantly higher levels of stemness 
genes while maintaining equivalent migration capacities 
compared to KIAA1114low cells. In contrast, SK-Hep-1 
sorted KIAA1114high cells displayed markedly enhanced 
migration without the upregulation of stemness-related 
markers. Such discrepancies in the nature of TICs isolated 
from distinct HCC subtypes is well-characterized in a 
recent study, which showed that EpCAM+ cells isolated 
from AFP+ cell lines exerted highly tumorigenic properties 
in vivo and expressed hepatic stem cell-associated genes 
while lacking capacities to metastasize [9]. Conversely, 
CD90+ cells was unable to produce large subcutaneous 
tumors but capable of forming lung metastases with 
upregulated expression of mesenchymal lineage 
markers. Although genomic profiles of KIAA1114high and 
KIAA1114low cells were not extensively investigated in the 
current study, it is reasonable to predict that KIAA1114high 
cells purified from SK-Hep-1 cells might have increased 
expression of genes associated with metastatic progression 
or EMT. Aside from KIAA1114, CD13 was the only 
marker to be expressed in both AFP+ and AFP− cell lines, 
but it remains to be determined whether CD13 could 
mark tumorigenic populations in AFP− HCCs. To our 
knowledge, this is the first experimental study to isolate 
tumorigenic, liver TIC-like populations from both AFP+ 
and AFP− HCC subtypes utilizing a single biomarker.
A potential function of MAGE family members as a 
marker for (cancer) stem cells has been initially proposed 
by Simpson et al. that cancer-testis antigens encoded by 
genes located on X chromosome, including MAGE-A, -B, 
-C, and -D, are frequently expressed in the spermatogonia, 
and therefore serve a putative role in marking male germ 
line stem cells [36]. Definitive experimental evidence 
for the association of MAGE proteins with stem cell 
phenotype was later provided by expression profiling 
studies of various types of human stem cells. For instance, 
MAGE-A and N-RAGE (also known as MAGE-D1) were 
Table 1: In vivo tumorigenicity of KIAA1114high and KIAA1114low cells isolated from HuH7 and 
SK-Hep-1 cell lines
Cell type Cell numbers injected
No. of mice with tumors / Total No. of mice injected
2 Months 3 months 4 months
HuH7 KIAA1114high 1,000 0/4 2/4 2/2
10,000 2/4 2/2
100,000 4/4
HuH7 KIAA1114low 1,000 0/4 0/4 0/4
10,000 0/4 0/4 1/4
100,000 1/4 2/3 1/1
SK-Hep-1 KIAA1114high 1,000 0/4 0/4 0/4
10,000 0/4 1/4 1/3
100,000 3/4 1/1
SK-Hep-1 KIAA1114low 1,000 0/4 0/4 0/4
10,000 0/4 0/4 0/4
100,000 0/4 0/4 0/4
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expressed by mesenchymal stem cells, but their expression 
levels decreased upon the differentiation of stem cells 
[37]. Similarly, the expression of MAGE-A3 and -A6 were 
detected in embryonic stem cells, but not in differentiated 
derivatives [38]. In addition, global gene expression 
analysis of CD133+ cells isolated from four different 
cord blood units identified trophinin as one of 32 genes 
that encode membrane proteins selectively expressed on 
CD133+ hematopoietic stem cells [39]. Although specific 
functions and mechanisms of these MAGE proteins in 
stem cell biology remain largely unknown, all of the 
above-mentioned studies implicate the potential role of 
MAGE family members in the regulation of stem cell 
maintenance or differentiation. More importantly, gene 
expression analysis of 31 different cancer-testis antigens 
in tumor spheres derived from 4 human glioma cell lines 
and a primary tumor specimen revealed that MAGE-D3 
(which is equivalent to trophinin) was the only gene 
that showed increased expression in all examined tumor 
spheres compared to their differentiated counterparts 
[40]. Since sphere-forming cells are known to exhibit 
higher self-renewal capacity, proliferative potential, drug 
resistance, and in vivo tumorigenic/metastatic capabilities 
than parental tumor cells [32, 41], trophinin gene products 
including KIAA1114 may be involved in promoting one 
or more of these biological processes in glioma model 
as well. Therefore, these findings raise the possibility 
that KIAA1114 may not only play a role as an alternate 
marker of hematopoietic stem cells, but also act as a 
broad-spectrum TIC marker for various types of tumors, 
including HCC and glioma.
In summary, our study characterized KIAA1114 as 
a novel cell-surface marker of liver TICs using human 
HCC cell lines and showed that isolated KIAA1114high 
fractions from two different HCC subsets (AFP+ and 
AFP−) displayed subtype-specific TIC features, resembling 
those of EpCAM+ TICs in AFP+ HCC and CD90+ TICs 
in AFP− HCC. Although the applicability of KIAA1114 
as a single biomarker to isolate TICs from multiple HCC 
subtypes offers unique advantages over other established 
TIC markers, it is crucial to validate its function by sorting 
KIAA1114high cells from clinical samples. We could not 
resolve this issue due to stringent regulatory restrictions on 
the acquisition of human primary solid tumor specimens 
imposed by institutional review boards in Korean domestic 
hospitals. However, substantial evidence has been 
provided by a number of studies that many known liver 
TIC markers verified in cell lines were also applicable to 
primary HCC. For instance, a previous study has shown 
that functional CD90+ cells could be isolated from 13 
out of 28 HCC specimens and all of them could initiate 
tumor growth in immunodeficient mice with ≤10,000 cells 
within four months [25]. Similarly, EpCAM+ and CD24+ 
cells derived from patient samples displayed superior 
tumorigenic capabilities in vivo than did EpCAM− and 
CD24− counterparts, respectively [8, 27]. Considering the 
overlapping pattern of expression between existing liver 
TIC markers and KIAA1114 and the resemblance in the 
functional features of isolated KIAA1114high cells to those 
of EpCAM+ and CD90+ cells, it is tempting to speculate 
that KIAA1114 could serve a parallel role in patient-
derived tumors as a TIC marker.
MATERIALS AND METHODS
Anti-human KIAA1114 mAb generation
Murine hybridoma cell line producing anti-KIAA1114 
mAb was kindly provided by Genexine Co., Ltd.. Briefly, 
Balb/c mice were immunized with a gene encoding 
N-terminal region (amino acids 1-366) of human KIAA1114. 
Splenocytes were collected from immunized mice and fused 
with SP2/0 myeloma cells. The hybridoma clone secreting 
mAb with the strongest antigen binding activity was selected 
and further characterized. mAb derived from selected clone 
was designated Kiatomab (IgG2b, κ). For the production of 
Kiatomab, Balb/c mice were first intraperitoneally treated 
with 500 μl Pristane (Sigma Aldrich). After 7 days, 5 X 106 
cells of hybridoma were injected intraperitoneally and the 
ascitic fluid was collected when abdominal bloating was 
observed. The purification of mAb was conducted with the 
AKTA purifier system using HiTrap Protein G HP column 
(GE Healthcare).
Cell lines
Human CC cell lines and a HCC cell line, SH-J1, 
were kindly provided by Dr. Dae-Ghon Kim (Chonbuk 
National University Medical School, Korea) and grown 
in DMEM (WelGENE). Other HCC cell lines were 
generously provided by Dr. Kwan Yong Choi (POSTECH, 
Korea) and grown in RPMI1640 (WelGENE). Human 
embryonic kidney 293T cell line was purchased from 
American Type Culture Collection and maintained in 
recommended medium. All medium was supplemented 
with 10% FBS (Thermo Scientific) and antibiotic-
antimycotic (Invitrogen).
Mice
Balb/c mice were purchased from Charles River 
Breeding Laboratories. Beige/nude/XID mice were 
purchased from The Jackson Laboratory. Animals were 
maintained under specific pathogen-free conditions. All 
animal procedures were approved by the Animal Care 
Committee of POSTECH Biotech Center.
Western blotting
Cell lysis was performed as previously described 
[42]. Whole cell lysates were incubated in 37°C for 
30 minutes, resolved in 4–15% Mini-PROTEIN TGX 
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Precast Gel (Bio-Rad), and transferred to nitrocellulose 
membrane (Whatman). Membranes were blocked 1 hour 
with 5% non fat dry milk in 0.1% Tween TBS (TBST) 
and further incubated overnight at 4°C with Kiatomab or 
anti-TROPHININ mAb (clone 3–11) (Abcam) diluted in 
blocking buffer. After washing with TBST, membranes were 
incubated at room temperature for 1 hour with horseradish 
peroxidase (HRP)-conjugated anti-mouse IgG (Bio-rad). 
Immunoreactive bands were stained with Super Signal West 
Pico Chemiluminescent kit (Pierce) and exposed to X-ray 
film. For Western blot analysis of extracted proteins from 
tissue, mouse brain tissues were minced and homogenized 
in 3ml RIPA buffer per gram of tissue. After centrifugation, 
supernatant containing the total cell lysate was removed 
and subjected to SDS-PAGE. Human liver whole tissue 
lysate and paired primary tumor and normal tissues were 
purchased from Novus Biologicals.
Flow cytometry
Single cell suspensions from diverse murine tissues 
were prepared as previously described [43]. Cells were 
resuspended in FACS buffer (PBS/1% FBS) containing 
Kiatomab or purified mouse IgG2b isotype antibody 
(eBioscience) and incubated on ice for 15 minutes. After 
being washed with FACS buffer, cells were incubated 
with allophycocyanin (APC)-conjugated goat anti-mouse 
Ig (BD Biosciences). For double fluorescence staining, 
cells were additionally stained with phycoerythrin (PE)-
conjugated CD133 (MiltenyiBiotec), CD90, EpCAM, 
CD24, or CD13 (eBioscience). Single cell sorting was 
performed with MoFlo XDP cell sorter (Beckman Coulter) 
by gating the top 10% of the most brightly fluorescent cells 
and the bottom 10% of the most dimly fluorescent cells.
Colony and sphere formation assay
Colony- and sphere-formation assays were 
performed as previously described [26, 44]. Cells were 
seeded at a density of 2000 cells per well and the resulting 
colonies or spheres were counted under the microscope 
at day 14.
Stemness gene expression analysis
RNA extraction and cDNA synthesis from isolated 
KIAA1114high and KIAA1114low cells were performed 
using Total RNA Extraction Kit (Intron Biotechnology) 
and QuantiTect Reverse Transcription Kit (Qiagen), 
respectively. Real-time PCR was performed on a Viaa 
7 real-time PCR system (Applied Biosystems) with 
various stemness gene-specific primers (Supplementary 
Table 3) and SYBR Green PCR Master Mix (Applied 
Biosystems).
Transwell migration assay
5 X 104 cells of HuH7-sorted or 1 X 104 cells of 
SK-Hep-1 sorted fractions were resuspended in serum-free 
medium and placed into the upper chambers of 24-well 
transwell (8 μm pore size; Corning). The lower chambers 
were filled with the medium containing 10% FBS. After 
incubating transwells at 37°C for 16 hours, migrated 
cells were stained using Diff-Quik Stain Set (Dade 
Behring, Inc.) and counted in 16 random fields under the 
microscope.
In vivo tumorigenicity assay
Beige/nude/XID mice were subcutaneously injected 
with various numbers of sorted KIAA1114high and 
KIAA1114low cells. Mice were monitored up to 4 months 
for the formation of palpable tumors.
Statistics
Data were expressed as mean ± SEM. Statistical 
differences between groups were calculated by a 2-tailed 
Student t test.
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